JAK2 and neoplasm: Although a baseline ctDNA sample is lacking for temporal resolution, the stark contrast between the primary tumor’s molecular profile and the subsequent liquid biopsy suggests that EGFR amplification and JAK2 p.V617F emerged during disease progression, possibly as a consequence of therapy-induced selective pressure or metastatic adaptation.